This trial is testing a new cancer treatment called DaRT. The goal is to find out how well it works and how safe it is.
- Squamous Cell Carcinoma
2 Primary · 7 Secondary · Reporting Duration: Up to 12 months following DaRT insertion
1 Treatment Group
1 of 1
86 Total Participants · 1 Treatment Group
Primary Treatment: DaRT seeds · No Placebo Group · N/A
Who is running the clinical trial?
Age 18+ · All Participants · 24 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
What is the objective of this investigation?
"This trial will assess the Duration of Response and other objectives, such as DaRT-related Adverse Events (evaluated using CTCAE v5), Patients Quality Of Life Assessment via Skin Cancer Index and Skindex-16 questionnaires, and Time of Local Control. This evaluation period is expected to last from Day 14 until 52 weeks." - Anonymous Online Contributor
Are researchers currently seeking participants for this experiment?
"According to the data on clinicaltrials.gov, this medical trial is still enrolling participants. Initially posted on September 21st 2022 and subsequently updated in November of that same year, further subjects are being sought for inclusion in the study." - Anonymous Online Contributor
What is the upper limit of participants involved in this experiment?
"This medical trial necessitates the participation of 86 qualified individuals in order to commence. Individuals can partake at either University Cancer & Diagnostic Center located in Houston, Texas or West Cancer Center situated in Germantown, Tennessee." - Anonymous Online Contributor